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Table 1. Univariate Analysis of Hemodynamic Parameters as Predictors of 30
Day Outcomes
N¼120 Pre-TAVR
30 Day
Death or
Readmission
(Prob >ChiSq)
Post-TAVR
Day 1
30 Day
Death or
Readmission
(Prob>ChiSq)
p-Value for
Change in
Hemodynamics
Post TAVR
RAP
(mmHg)
11.6+/-4.22 0.3146 7.36 +/-3.68 0.4608 <0.0001
PASP
(mmHg)
40.4+/-12.3 0.8588 37.2+/-9.55 0.6468 0.0016
PADP
(mmHg)
20.5+/-7.2 0.7086 16.6+/-5.56 0.6529 <0.0001
MPAP
(mmHg)
28.5+/-9 0.8343 23.1+/-6.41 0.9850 <0.0001
CO (L/min) 3.83+/-1.33 0.4437 4.67+/-1.63 0.0482* <0.0001
CI
(L/min/m2)
2.08+/-0.7l 0.6866 2.56 +/-0.9 0.115 <0.0001
PVR
(Woods
units-m2)
2.32+/-2.54 0.8621
TPG
(mmHg)
8.05+/-6.9 0.8969
RVSWI
(mmHg
x mL/m2)
5.46 +/- 4.81 0.2827 6.9 +/- 3.9 0.049* 0.0003
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TAVI.
Methods: All consecutive patients undergoing transfemoral or transapical TAVI in
our centre were prospectively enrolled from June 2007 to December 2013. LVEF was
measured using the Simpson biplane method and classiﬁed as good (50%), moderate
(31-50%), and severely impaired (30%) at transthoracic echocardiography not later
than 3 months before TAVI.
Results: In total, 263 (mean age 81.67.5, male 41.8%, logistic EuroSCORE
23.215.0%) and 224 (mean age 80.06.5, male 46.0%, logistic EuroSCORE
27.416.6%) patients underwent transfemoral and transapical TAVI, respectively. In
the transfemoral group, LVEF was 50%, 31-50%, and 30% in 170 (64.6%), 67
(25.5%) and 26 (9.9%) of patients, respectively. In the transapical group, LVEF was
50%, 31-50%, and 30% in 149 (66.5%), 52 (23.2%) and 23 (10.3%) of patients,
respectively. Thirty-day all-cause mortality was not associated with LVEF. An
impaired LVEF < 50% predicted 2-year mortality for transapical (HR 1.86, 95% CI
1.06 to 3.26, p¼0.03) but not transfemoral TAVI (HR 0.82, 95% CI 0.39 to 1.69,
p¼0.58) after multivariate adjustment.
Conclusions: An impaired LVEF before TAVI affects the prognosis differently per
TAVI approach. The LVEF may be considered in deciding the most appropriate
approach for TAVI.
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Background: The Aortic Valve Academic Research Consortium (VARC) endpoint
deﬁnitions were established to standardize the evaluation of clinical outcomes
following transcatheter aortic valve implantation (TAVI). It remains unclear, however,
to what extent and in which manner these deﬁnitions are used in publications.
Methods:We performed a systematic review of the literature to identify TAVI-related
manuscripts published between Feb. 2011 and Feb. 2014. Two physicians indepen-
dently reviewed these manuscripts and categorized them into 3 groups: a ’compliant’
group comprised of VARC-deﬁned endpoints only, a ’non-compliant’ group
comprised of non-VARC-deﬁned endpoints only, and a ’mixed compliant’ group
comprising VARC- and non-VARC-deﬁned endpoints.
Results: The search yielded a total of 5023 manuscripts and 514 were included in the
analysis. At least one VARC deﬁnition was used in 275 (54%) manuscripts while 223
(43%) did not use any VARC deﬁnitions. We excluded from the analysis 16 (3%)
manuscripts which dealt with outcomes not deﬁned in VARC. Of the manuscripts
using VARC, 49 (10%) were classiﬁed as compliant and 226 (46%) as mixed
compliant. The following endpoints were more often deﬁned using VARC vs. non-
VARC: MI (64% vs 36%), stroke (56% vs. 44%), bleeding and (79% vs 21%)
vascular complications (70% vs. 30%), AKI (63% vs. 37%), reintervention (67% vs.
33%) and composite endpoints (52% vs. 48%). The following endpoints were less
often deﬁned using VARC vs. non-VARC: mortality (59% vs 41%), valve-dysfunc-
tion (82% vs. 18%), TAVI-related complications (59% vs. 41%), NYHA (73% vs.
27%) and QOL (91% vs. 9%). After publication of the ﬁrst VARC manuscript, VARC
usage in TAVI publications increased from 29% at 6 months to 59% at 30 months.
After publication of the revised VARC deﬁnitions VARC-2 usage increased from 3%
at 6 months to 27% at 18 months, while VARC usage in general remained at 54%.
Conclusions: Although VARC deﬁnitions are well accepted within the “community”,
usage in peer-reviewed manuscripts remains suboptimal. Further studies are warranted
to better understand how to improve compliance and adapt these ﬁndings in future
VARC iterations.
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Background: Right ventricular function and pulmonary hypertension are often not
taken into consideration in the prognostication of patients undergoing TAVR;
accordingly their impact on patients undergoing TAVR remains relatively poorly
deﬁned. We sought to explore their effect on 30 day outcomes in patients undergoing
TAVR.
Methods: We collected complete baseline demographic and hemodynamic data ob-
tained by right heart catheterization on 120 consecutive patients undergoing TAVR at
our institution over a 1 year period. 30 day rate of death or hospital readmission were
then examined. Statistical calculations were performed using JMP software.
Results: There were 5 deaths and 5 readmissions within 30 days. Mean age was 82.8
+/-8.2 years, BSA 1.82 +/-0.26m2, STS score 8.14 +/- 5.53, aortic valve area (AVA)
0.63+/-0.16cm2, mean gradient 50.4+/-13.7mmHg, creatinine 1.37+/-0.82 mg/dL,
MELD score 10.4+/-4.3, and length of stay 5.5+/-4.5 days. 61.7% were female, 84.2%JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Vahypertensive, 34.2% diabetic, and 74.2% had coronary artery disease. 63.3% pro-
cedures were transfemoral (TF), 33.3% transapical (TA), and 3.3% trans-aortic (Tao).
Trends toward higher event rates were seen with higher STS scores, lower pre-operative
AVA, mean gradients, left ventricular ejection fraction (LVEF),cardiac output (CO),
cardiac index (CI) or that had TA access. Low post-operative CO and right ventricular
stroke work index (RVSWI) were associated with statistically signiﬁcant higher 30 day
mortality and readmission rates. Pre- or post-operative right atrial pressure (RAP),
pulmonary capillary wedge pressue (PCWP), trans-pulmonary gradient (TPG), pul-
monary vascular resistence (PVR), creatinine, and MELD score had no effect (Table 1).Conclusions: TAVR results in statistically signiﬁcant improvements in most hemo-
dynamic parameters. Poor post-TAVR CO and RVSWI were the strongest hemody-
namic parameters of death or readmission after 30 days.
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Background: Signiﬁcant aortic regurgitation (AR), in particular paravalvular AR,
remains a relevant complication in patients undergoing transcatheter aortic valve
implantation (TAVI) for symptomatic aortic stenosis. It remains unknown whether
postdilatation (PD) as a treatment for paravalvular AR after TAVI improves AR and
interferes with clinical outcome. The aim of this study was to investigate the impact of
PD to reduce paravalvular AR after TAVI and its potential relevance for long-term
survival.
Methods: 416 patients underwent TAVI at our institution from 2008-2013 using
balloon-expandable Edwards Sapien and Sapien XT prostheses. 406 pts were avail-
able for complete retrospective analyses. The severity of paravalvular AR was eval-
uated by procedural angiography and, in a subgroup of patients, also with
echocardiography 7d and 1 y after TAVI. Decision to postdilate or not was made by
the team of implanting physicians immediately after valve deployment. The severity
of AR for these analyses was evaluated by investigators blinded to the outcome.
Results: At a median follow-up of 308d (IQR 92-670), a total of n¼143 deaths
occurred, 30d mortality was 7.9% (n¼32). 54.2% were treated via transfemoral (30d
mortality 4.1%), 33.7% transapical (30d mortality 14.6%) and 12.1% transaortic ac-
cess (30d mortality 6.1%). Mean age was 81.4y (6.15), 56.7% were females, the
mean log. EuroScore was 27.5% (17.3). PD was carried out in n¼137/406 pts
(33.7%) and led to a signiﬁcant reduction of paravalvular AR (Chi-square test p<
0.001). Of note, PD was not associated with increased complications according to
VARC-2 criteria (including new pacemaker, p¼0.66, and periprocedural stroke
p¼0.55, Irwin-Fisher Test). A signiﬁcant postprocedural AR (> grade 1+) was
associated with a worse prognosis in the total n¼406 cohort (HR 1.69, CI 1.1-2.5).
Conclusions: These ﬁndings indicate that PD of ballon-expandable TAVI valves is a
safe and efﬁcient method to reduce paravalvular AR. In addition, this study shows that
pts undergoing PD do not have an inferior prognosis as expected according their initial
AR (p¼0.302). Further investigations will address the long-term follow-up including
AR and durability of postdilated valves.lvular disease - Aortic: TAVR B215
